Humacyte FY2026 Earnings Forecast Boosted by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for Humacyte in a report released on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.39) for the year, up from their previous estimate of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2026 earnings at ($0.10) EPS, Q1 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.11) EPS.

HUMA has been the subject of a number of other reports. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Benchmark cut their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research report on Thursday, August 13th. Barclays boosted their price objective on Humacyte from $0.50 to $0.60 and gave the stock an “equal weight” rating in a research note on Wednesday. Williams Trading set a $1.00 target price on Humacyte in a research report on Friday, October 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.48.

Humacyte Price Performance

Humacyte stock opened at $0.60 on Friday. Humacyte has a 52-week low of $0.34 and a 52-week high of $1.52. The firm has a fifty day moving average of $0.49 and a 200-day moving average of $0.78. The firm has a market capitalization of $165.40 million, a P/E ratio of -1.35 and a beta of 2.64. The company has a quick ratio of 5.74, a current ratio of 3.34 and a debt-to-equity ratio of 3.65.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 3,955.05% and a negative return on equity of 612.88%. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. Beacon Pointe Advisors LLC bought a new position in Humacyte during the 2nd quarter valued at $28,000. Bank of New York Mellon Corp bought a new stake in shares of Humacyte in the 2nd quarter valued at approximately $44,000. Sei Investments Co. acquired a new stake in shares of Humacyte during the 1st quarter valued at approximately $56,000. Miramontes Capital LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $85,000. Finally, LaSalle St. Investment Advisors LLC bought a new position in Humacyte during the second quarter worth $89,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte News Summary

These are some of the HUMA news items that stood out recently:

• Positive Sentiment: Humacyte plans to present five ATEV and Symvess updates at the VEITHsymposium, including interim Phase 3 data in women receiving hemodialysis and integrated results from three dialysis-access trials. The company also expects to submit a supplemental BLA for hemodialysis access in November. The presentations may draw attention to its pipeline, though the data have not yet been presented. Humacyte VEITHsymposium announcement
• Positive Sentiment: StoneX reiterated its “Speculative Buy” rating, offering a supportive analyst view, although the reiteration itself is not a new upgrade. StoneX rating coverage
• Negative Sentiment: The broker cut its Q3 and Q4 2027 forecasts by $0.01 per share each, lowered FY2027 estimates to a loss of $0.31 per share from $0.30, and reduced its FY2028 estimate to a loss of $0.11 from $0.07. These changes suggest weaker expected earnings further out.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.